-0.39%
-16.83%
-48.08%
-62.37%
-50.10%
-45.09%
-75.52%
AI Spotlight on TCRX
Company Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.
It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer.TScan Therapeutics, Inc.was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Market Data
| Last Price | 2.57 |
| Change Percentage | -0.39% |
| Open | 2.6 |
| Previous Close | 2.58 |
| Market Cap ( Millions) | 137 |
| Volume | 209517 |
| Year High | 9.69 |
| Year Low | 2.31 |
| M A 50 | 3.38 |
| M A 200 | 5.77 |
Financial Ratios
| FCF Yield | -80.62% |
| Dividend Yield | 0.00% |
| ROE | -58.72% |
| Debt / Equity | 39.44% |
| Net Debt / EBIDTA | 41.55% |
| Price To Book | 1.33 |
| Price Earnings Ratio | -2.74 |
| Price To FCF | -1.24 |
| Price To sales | 14.65 |
| EV / EBITDA | -0.92 |
News
- Jan -10 - Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
- Dec -26 - TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
- Dec -23 - TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
- Dec -09 - TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
- Dec -05 - TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
- Dec -02 - TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
- Nov -12 - TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
- Nov -07 - TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
- Nov -05 - TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
- Oct -04 - TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
- Aug -29 - TScan Therapeutics to Participate in Upcoming Investor Conferences
- Aug -12 - TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
- Aug -12 - TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Jun -14 - TScan Therapeutics Announces Updates to its Board of Directors
- May -30 - TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
- May -29 - TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
- May -13 - TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
- May -13 - TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- May -09 - TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
- May -01 - TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> T Cell Receptor-engineered T Cell
Expected Growth : 11.7 %
What the company do ?
T Cell Receptor-engineered T Cell from TScan Therapeutics, Inc. is a personalized cancer therapy that uses genetically modified T cells to target and kill cancer cells.
Why we expect these perspectives ?
TScan Therapeutics' T Cell Receptor-engineered T Cell growth is driven by increasing adoption in cancer treatment, advancements in gene editing technologies, and a growing demand for personalized therapies. Additionally, strategic partnerships, expanding clinical trials, and a strong pipeline of candidates contribute to the 11.7% growth.
Tscan Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| TCR Therapies | TScan Therapeutics develops T cell receptor (TCR) therapies that harness the power of the immune system to target and eliminate cancer cells. |
| Neoantigen-based Therapies | TScan Therapeutics identifies and targets tumor-specific neoantigens to develop personalized cancer therapies. |
| TCR-based Companion Diagnostics | TScan Therapeutics develops companion diagnostics to identify patients most likely to respond to TCR therapies. |
TScan Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
TScan Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative cancer treatment options, but the company's focus on T-cell receptor therapy provides a unique value proposition.
Bargaining Power Of Customers
TScan Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for effective cancer treatments.
Bargaining Power Of Suppliers
TScan Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment, but the company's dependence on a few key suppliers for critical components.
Threat Of New Entrants
TScan Therapeutics, Inc. has a high threat of new entrants due to the growing interest in T-cell receptor therapy and the potential for new companies to enter the market with innovative technologies.
Intensity Of Rivalry
TScan Therapeutics, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry among companies developing T-cell receptor therapies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 18.08% |
| Debt Cost | 4.07% |
| Equity Weight | 81.92% |
| Equity Cost | 8.44% |
| WACC | 7.65% |
| Leverage | 22.07% |
TScan Therapeutics, Inc. : Quality Control
TScan Therapeutics, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CSBR | Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach … |
| DNTH | Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
| ONCT | Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal … |
| TARS | Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Dianthus Therapeutics
A-Score
1-Year Total Return ->
🥈
Kymera Therapeutics
A-Score
1-Year Total Return ->
🥉
Tarsus Pharmaceuticals
A-Score
1-Year Total Return ->
4
Champions Oncology
A-Score
1-Year Total Return ->
5
Oncternal Therapeutics
A-Score
1-Year Total Return ->
6
